Charles Schwab
AKCA

Charles Schwab’s Akcea Therapeutics Inc AKCA Stock Holding History

Charles Schwab’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-110,837
Closed -$2.01M – 3443
2020
Q3 		$2.01M Sell
110,837
-66,578
-38% -$944K ﹤0.01% 2489
2020
Q2 		$2.43M Buy
177,415
+15,886
+10% +$245K ﹤0.01% 2353
2020
Q1 		$2.31M Buy
161,529
+9,125
+6% +$150K ﹤0.01% 2219
2019
Q4 		$2.58M Buy
152,404
+45,245
+42% +$842K ﹤0.01% 2342
2019
Q3 		$1.65M Buy
107,159
+18,436
+21% +$393K ﹤0.01% 2448
2019
Q2 		$2.08M Buy
88,723
+2,035
+2% +$50.3K ﹤0.01% 2358
2019
Q1 		$2.46M Buy
86,688
+3,401
+4% +$99.1K ﹤0.01% 2294
2018
Q4 		$2.51M Buy
83,287
+10,634
+15% +$298K ﹤0.01% 2245
2018
Q3 		$2.54M Buy
72,653
+1,593
+2% +$48.2K ﹤0.01% 2354
2018
Q2 		$1.69M Sell
71,060
-5,082
-7% -$121K ﹤0.01% 2426
2018
Q1 		$1.95M Buy
76,142
+8,424
+12% +$181K ﹤0.01% 2342
2017
Q4 		$1.18M Buy
67,718
+7,957
+13% +$156K ﹤0.01% 2467
2017
Q3 		$1.65M Buy
+59,761
New +$1.11M ﹤0.01% 2353

Charles Schwab's AKCA Position: Q4 2020 in Review

Charles Schwab sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 110,837 shares — an estimated $2.01M sold.

Charles Schwab first reported a position in AKCA in Q3 2017 and held it in 13 quarters. The position peaked at $2.58M in Q4 2019. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

  • Charles Schwab reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
  • Charles Schwab sold 110,837 Akcea Therapeutics Inc shares in Q4 2020, an estimated $2.01M.
  • Charles Schwab first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 13 quarters.
  • Charles Schwab's Akcea Therapeutics Inc position peaked at $2.58M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on Charles Schwab's 13F filing for Q4 2020, filed 16 Feb 2021.